Login to Your Account



AM-Pharma opts for adaptive design route after successful phase I

By Nuala Moran
Staff Writer

Tuesday, March 25, 2014
LONDON – AM-Pharma has cleared the way to getting its alkaline phosphatase product back into patient trials after reporting positive results in a phase I study in 50 healthy volunteers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription